These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 33376742)

  • 1. A New Method for Imputing Censored Values in Crossover Designs with Time-to-Event Outcomes Using Median Residual Life.
    Jalali M; Bagheri Z; Zare N; Ayatollahi SMT
    Biomed Res Int; 2020; 2020():8475154. PubMed ID: 33376742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incorporating baseline measurements into the analysis of crossover trials with time-to-event endpoints.
    Xu R; Mehrotra DV; Shaw PA
    Stat Med; 2018 Oct; 37(23):3280-3292. PubMed ID: 29888552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A semiparametric imputation approach for regression with censored covariate with application to an AMD progression study.
    Ding Y; Kong S; Kang S; Chen W
    Stat Med; 2018 Oct; 37(23):3293-3308. PubMed ID: 29845616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple imputation for interval censored data with auxiliary variables.
    Hsu CH; Taylor JM; Murray S; Commenges D
    Stat Med; 2007 Feb; 26(4):769-81. PubMed ID: 16755528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple imputation for cure rate quantile regression with censored data.
    Wu Y; Yin G
    Biometrics; 2017 Mar; 73(1):94-103. PubMed ID: 27479513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple imputation based on restricted mean model for censored data.
    Liu LX; Murray S; Tsodikov A
    Stat Med; 2011 May; 30(12):1339-50. PubMed ID: 21560139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A two-sample test with interval censored data via multiple imputation.
    Pan W
    Stat Med; 2000 Jan; 19(1):1-11. PubMed ID: 10623909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Approximating the baseline hazard function by taylor series for interval-censored time-to-event data.
    Chen DG; Yu L; Peace KE; Lio YL; Wang Y
    J Biopharm Stat; 2013 May; 23(3):695-708. PubMed ID: 23611204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CondiS: A conditional survival distribution-based method for censored data imputation overcoming the hurdle in machine learning-based survival analysis.
    Wang Y; Flowers CR; Li Z; Huang X
    J Biomed Inform; 2022 Jul; 131():104117. PubMed ID: 35690348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. On the role of Baseline measurements for crossover designs under the self and mixed carryover effects model.
    Liang Y; Carriere KC
    Biometrics; 2010 Mar; 66(1):140-8. PubMed ID: 19432775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regression models for interval censored data using parametric pseudo-observations.
    Johansen MN; Lundbye-Christensen S; Larsen JM; Parner ET
    BMC Med Res Methodol; 2021 Feb; 21(1):36. PubMed ID: 33588771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A two-step semiparametric method to accommodate sampling weights in multiple imputation.
    Zhou H; Elliott MR; Raghunathan TE
    Biometrics; 2016 Mar; 72(1):242-52. PubMed ID: 26393409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple imputation for patient reported outcome measures in randomised controlled trials: advantages and disadvantages of imputing at the item, subscale or composite score level.
    Rombach I; Gray AM; Jenkinson C; Murray DW; Rivero-Arias O
    BMC Med Res Methodol; 2018 Aug; 18(1):87. PubMed ID: 30153796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of statistical issues with progression-free survival as an interval-censored time-to-event endpoint.
    Sun X; Li X; Chen C; Song Y
    J Biopharm Stat; 2013; 23(5):986-1003. PubMed ID: 23957511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of baseline covariates on the efficiency of statistical analyses of crossover designs.
    Yan Z
    Stat Med; 2013 Mar; 32(6):956-63. PubMed ID: 22903413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multiple imputation approach for clustered interval-censored survival data.
    Lam KF; Xu Y; Cheung TL
    Stat Med; 2010 Mar; 29(6):680-93. PubMed ID: 20069624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of trial design on the estimation of drug potency and power in clinical trials of haemophilia with inhibitors.
    Larsen MS; Juul RV; Kreilgaard M; Kristensen AT; Simonsson USH
    Eur J Pharm Sci; 2018 Oct; 123():531-538. PubMed ID: 30077714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficient baseline utilization for incomplete block crossover clinical trials.
    Jemielita TO; Putt ME; Mehrotra DV
    Stat Methods Med Res; 2019 Mar; 28(3):801-821. PubMed ID: 29179645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Power and Sample Size Calculations for Contrast Analysis in ANCOVA.
    Shieh G
    Multivariate Behav Res; 2017; 52(1):1-11. PubMed ID: 28121163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The multiple imputation method: a case study involving secondary data analysis.
    Walani SR; Cleland CM
    Nurse Res; 2015 May; 22(5):13-9. PubMed ID: 25976532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.